Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer

BACKGROUND: Docetaxel is the first-line chemotherapy for castration-resistant prostate cancer (CRPC). However, response rates are ∼50% and determined quite late in the treatment schedule, thus non-responders are subjected to unnecessary toxicity. The potential of circulating microRNAs as early bioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, H-M, Castillo, L, Mahon, K L, Chiam, K, Lee, B Y, Nguyen, Q, Boyer, M J, Stockler, M R, Pavlakis, N, Marx, G, Mallesara, G, Gurney, H, Clark, S J, Swarbrick, A, Daly, R J, Horvath, L G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021524/
https://www.ncbi.nlm.nih.gov/pubmed/24714754
http://dx.doi.org/10.1038/bjc.2014.181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021524/
https://www.ncbi.nlm.nih.gov/pubmed/24714754
http://dx.doi.org/10.1038/bjc.2014.181

Ejemplares similares